Tinidazole (500mg) + Clarithromycin (250mg) + Lansoprazole (30mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) therapy primarily indicated for the eradication of Helicobacter pylori (H. pylori) in patients with peptic ulcer disease and gastritis. This triple therapy leverages the synergistic antimicrobial effects of Tinidazole (a nitroimidazole antibiotic) and Clarithromycin (a macrolide antibiotic) against H. pylori, while Lansoprazole (a proton pump inhibitor) suppresses gastric acid, enhancing antibiotic efficacy and promoting ulcer healing.

This combination acts synergistically to eradicate H. pylori. Lansoprazole potently inhibits the H+/K+ ATPase (proton pump) in gastric parietal cells, raising intragastric pH. This acid suppression: 1) Creates a hostile environment for H. pylori, 2) Increases the stability and bioavailability of acid-labile antibiotics (Clarithromycin), and 3) Promotes ulcer healing. Tinidazole enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA. Clarithromycin binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis.